Medable has launched a new support programme aimed at helping pharmaceutical companies and contract research organisations deploy artificial intelligence tools across clinical development operations.

The Agentic Accelerator Program is designed to provide implementation support, integration services, governance frameworks and change management for organisations adopting AI agents within clinical trial workflows.

According to the company, the programme will support customers using Medable Agent Studio, its platform for developing and deploying AI agents across clinical development activities.

The launch reflects growing interest in the use of AI to automate administrative and operational tasks throughout the clinical trial process, although adoption across the life sciences sector remains at an early stage.

Medable said the programme will provide customers with access to clinical development specialists and engineering support to help organisations deploy standard AI use cases while also building customised workflows.

Michelle Longmire, chief executive officer and co-founder of Medable, said: “Agentic AI is the productivity leverage that bends the time/cost curve of today’s clinical trials. Customers want rapid time to value while also ensuring protection of their proprietary agentic clinical development strategy.

“To achieve this, customers need a partner with industry expertise, a fit-for-purpose agentic platform, and a willingness to put skin in the game on the outcomes. Companies that want results choose Medable because it’s the fastest path to scalable agentic transformation for clinical trials.”

Medable said its Agent Studio platform supports the use of AI agents across clinical development activities ranging from protocol development to study close-out.

The platform includes tools for no-code agent creation, governance controls, human oversight mechanisms and integration capabilities intended to support regulated clinical research environments.

Interest in AI-enabled clinical development has increased significantly in recent years as sponsors seek to reduce administrative burden, improve operational efficiency and accelerate study execution. However, many organisations remain in the early stages of implementation and continue to evaluate governance, compliance and validation requirements associated with AI technologies.

The launch of the Agentic Accelerator Program reflects a broader trend across the pharmaceutical industry towards providing implementation and adoption services alongside AI software platforms as vendors seek to help customers move from pilot projects to wider deployment.